Guardant Health, Inc. $GH Shares Sold by Fuller & Thaler Asset Management Inc.

Key Points

• Fuller & Thaler Asset Management Inc. has reduced its stake in Guardant Health by 1.0%, now owning approximately 1.59% of the company, following the sale of 18,865 shares.
• Analysts have optimistic forecasts for Guardant Health, with multiple firms upgrading their ratings and increasing target prices, reflecting strong anticipated growth.
• Insider trading activity at Guardant Health included significant sales by directors, with a total of 235,400 shares sold recently, amounting to over $11 million.

Fuller & Thaler Asset Management Inc. lowered its holdings in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 1.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,965,721 shares of the company's stock after selling 18,865 shares during the quarter. Fuller & Thaler Asset Management Inc. owned 1.59% of Guardant Health worth $83,740,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. NewEdge Advisors LLC lifted its holdings in shares of Guardant Health by 13.5% in the 4th quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock valued at $59,000 after acquiring an additional 230 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of Guardant Health by 0.3% in the 1st quarter. American Century Companies Inc. now owns 104,206 shares of the company's stock worth $4,439,000 after purchasing an additional 282 shares during the period. HighTower Advisors LLC increased its position in shares of Guardant Health by 0.9% during the 1st quarter. HighTower Advisors LLC now owns 51,107 shares of the company's stock valued at $2,177,000 after purchasing an additional 469 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in Guardant Health by 25.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,638 shares of the company's stock valued at $112,000 after buying an additional 537 shares during the period. Finally, GF Fund Management CO. LTD. lifted its position in Guardant Health by 22.0% in the first quarter. GF Fund Management CO. LTD. now owns 3,164 shares of the company's stock worth $135,000 after buying an additional 570 shares during the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

Guardant Health Stock Performance

NASDAQ GH traded up $0.12 during mid-day trading on Friday, reaching $61.40. 2,002,878 shares of the stock were exchanged, compared to its average volume of 3,323,995. The company has a market capitalization of $7.66 billion, a P/E ratio of -18.33 and a beta of 1.43. The business's 50 day moving average is $50.26 and its 200-day moving average is $45.97. Guardant Health, Inc. has a 1 year low of $20.14 and a 1 year high of $62.81.

Guardant Health (NASDAQ:GH - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.08. The firm had revenue of $232.09 million for the quarter, compared to analysts' expectations of $211.19 million. The company's revenue was up 31.0% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.84) earnings per share. Guardant Health has set its FY 2025 guidance at EPS. Equities analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. UBS Group boosted their price objective on shares of Guardant Health from $65.00 to $70.00 and gave the company a "buy" rating in a research report on Thursday, May 1st. Scotiabank lifted their price target on shares of Guardant Health from $57.00 to $60.00 and gave the stock a "sector outperform" rating in a research note on Thursday, July 31st. Canaccord Genuity Group increased their price objective on shares of Guardant Health from $60.00 to $65.00 and gave the stock a "buy" rating in a research report on Thursday, May 1st. Mizuho raised their price objective on shares of Guardant Health from $60.00 to $65.00 and gave the stock an "outperform" rating in a research note on Friday, June 13th. Finally, Raymond James Financial boosted their target price on Guardant Health from $59.00 to $61.00 and gave the company an "outperform" rating in a research report on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating and sixteen have assigned a Buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $57.50.

Insider Transactions at Guardant Health

In related news, Director Ian T. Clark sold 6,672 shares of the business's stock in a transaction on Tuesday, June 17th. The shares were sold at an average price of $48.38, for a total value of $322,791.36. Following the completion of the sale, the director owned 9,851 shares of the company's stock, valued at approximately $476,591.38. The trade was a 40.38% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Myrtle S. Potter sold 2,626 shares of the firm's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $49.70, for a total transaction of $130,512.20. Following the completion of the transaction, the director directly owned 18,180 shares in the company, valued at approximately $903,546. This represents a 12.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 235,542 shares of company stock worth $11,852,491 in the last ninety days. Company insiders own 6.10% of the company's stock.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.